RemeGen Co., Ltd.* (Stock Code: 9995) released its unaudited 2025 third quarter report. Operating revenue during the January–September period reached approximately RMB1.72 billion, reflecting a 42.27% increase compared to the same period of the previous year. According to the announcement, the revenue growth was mainly driven by increased product sales volume and income from a new technology licensing agreement.

Net loss attributable to shareholders stood at about RMB550.70 million, narrowing from a higher loss in the previous year. The result was partly bolstered by pipeline optimizations and a license agreement executed with Vor Biopharma Inc., which reduced overseas clinical trial expenses for telitacicept. Research and development expenses totaled roughly RMB890.58 million for the first three quarters, representing a decrease of 22.79% from the prior year. Meanwhile, the net cash inflow from operating activities was around RMB217.06 million, primarily benefiting from technology licensing revenue and higher cash inflows from rising product sales.

Total assets increased to about RMB5.98 billion, up 8.70% from the end of 2024, while owners’ equity attributable to shareholders rose by 16.81% to approximately RMB2.32 billion. The company emphasized that these financial figures have not been audited by independent auditors and were prepared according to accounting principles of the People’s Republic of China, rather than International Financial Reporting Standards.